Cryolife Stock Upgraded (CRY)

NEW YORK (TheStreet) -- Cryolife (NYSE:CRY) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

• The revenue growth came in higher than the industry average of 7.3%. Since the same quarter one year prior, revenues slightly increased by 4.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
• CRY has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. To add to this, CRY has a quick ratio of 1.87, which demonstrates the ability of the company to cover short-term liquidity needs.
• Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Looking ahead, unless broad bear market conditions prevail, we still see more upside potential for this stock, despite the fact that it has already risen over the past year.
• The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 166.6% when compared to the same quarter one year prior, rising from -$3.03 million to $2.02 million.

.

CryoLife, Inc. engages in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries in the United States and Canada. The company has a P/E ratio of 20.4, above the average health services industry P/E ratio of 19 and above the S&P 500 P/E ratio of 17.7. Cryolife has a market cap of $150 million and is part of the health care sector and health services industry. Shares are up 22.1% year to date as of the close of trading on Wednesday.

You can view the full Cryolife Ratings Report or get investment ideas from our investment research center.
-- Written by a member of TheStreet RatingsStaff

For more information on Cryolife click any of the following:

• Cryolife Stock Price

• Cryolife Analyst Ratings

• Cryolife Key Stats & Profile

• Cryolife Earnings

• Cryolife Ratio Comparison

• Cryolife Growth Rates

• Cryolife Balance Sheet

• Cryolife Cash Flow

• Cryolife Income Statement